STOCK TITAN

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Indaptus Therapeutics (Nasdaq: INDP) announces that Chief Medical Officer Roger Waltzman, M.D., M.B.A. will moderate a panel at the upcoming CMO360 Summit in Boston on April 7-8, 2025. The panel, titled 'Ensuring Effective and Efficient Trials Through Clinical Operations,' is scheduled for April 7th from 4:05PM to 4:35PM ET.

The CMO Summit 360°, operated by The Conference Forum, represents the largest gathering of biotech Chief Medical Officers across various indications, modalities, company stages, and locations. CEO Jeffrey Meckler views this participation as validation of the company's approach to clinical trial management.

Indaptus Therapeutics (Nasdaq: INDP) annuncia che il Direttore Medico Roger Waltzman, M.D., M.B.A. modererà un panel al prossimo CMO360 Summit a Boston il 7-8 aprile 2025. Il panel, intitolato 'Garantire prove efficaci ed efficienti attraverso le operazioni cliniche', è programmato per il 7 aprile dalle 16:05 alle 16:35 ET.

Il CMO Summit 360°, organizzato da The Conference Forum, rappresenta il più grande raduno di Direttori Medici di biotech provenienti da varie indicazioni, modalità, fasi aziendali e località. Il CEO Jeffrey Meckler considera questa partecipazione come una convalida dell'approccio dell'azienda alla gestione delle sperimentazioni cliniche.

Indaptus Therapeutics (Nasdaq: INDP) anuncia que el Director Médico Roger Waltzman, M.D., M.B.A. moderará un panel en el próximo CMO360 Summit en Boston el 7-8 de abril de 2025. El panel, titulado 'Asegurando Ensayos Efectivos y Eficientes a Través de Operaciones Clínicas', está programado para el 7 de abril de 4:05PM a 4:35PM ET.

El CMO Summit 360°, operado por The Conference Forum, representa la mayor reunión de Directores Médicos de biotecnología de diversas indicaciones, modalidades, etapas de la empresa y ubicaciones. El CEO Jeffrey Meckler ve esta participación como una validación del enfoque de la empresa en la gestión de ensayos clínicos.

Indaptus Therapeutics (Nasdaq: INDP)는 최고 의료 책임자 Roger Waltzman, M.D., M.B.A.가 2025년 4월 7-8일 보스턴에서 열리는 CMO360 Summit에서 패널을 진행할 것이라고 발표했습니다. '임상 운영을 통한 효과적이고 효율적인 시험 보장'이라는 제목의 패널은 4월 7일 오후 4시 5분부터 4시 35분까지 예정되어 있습니다.

CMO Summit 360°는 The Conference Forum이 운영하며, 다양한 적응증, 방식, 회사 단계 및 위치에서 온 생명공학 최고 의료 책임자들의 최대 집합을 나타냅니다. CEO Jeffrey Meckler는 이 참여를 회사의 임상 시험 관리 접근 방식에 대한 검증으로 보고 있습니다.

Indaptus Therapeutics (Nasdaq: INDP) annonce que le Directeur Médical Roger Waltzman, M.D., M.B.A. animera un panel lors du prochain CMO360 Summit à Boston les 7 et 8 avril 2025. Le panel, intitulé 'Assurer des essais efficaces et efficients grâce aux opérations cliniques', est prévu pour le 7 avril de 16h05 à 16h35 ET.

Le CMO Summit 360°, organisé par The Conference Forum, représente le plus grand rassemblement de Directeurs Médicaux de biotechnologie provenant de diverses indications, modalités, étapes d'entreprise et localisations. Le PDG Jeffrey Meckler considère cette participation comme une validation de l'approche de l'entreprise en matière de gestion des essais cliniques.

Indaptus Therapeutics (Nasdaq: INDP) gibt bekannt, dass der Chief Medical Officer Roger Waltzman, M.D., M.B.A. ein Panel beim kommenden CMO360 Summit in Boston am 7.-8. April 2025 moderieren wird. Das Panel mit dem Titel 'Sichere effektive und effiziente Studien durch klinische Operationen' ist für den 7. April von 16:05 bis 16:35 Uhr ET geplant.

Der CMO Summit 360°, der von The Conference Forum organisiert wird, stellt das größte Treffen von Chief Medical Officers der Biotechnologie aus verschiedenen Indikationen, Modalitäten, Unternehmensphasen und Standorten dar. CEO Jeffrey Meckler sieht diese Teilnahme als Bestätigung des Ansatzes des Unternehmens im Management klinischer Studien.

Positive
  • None.
Negative
  • None.

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief medical officer, Roger Waltzman, M.D., M.B.A. will be moderating a panel at the annual CMO360 Summit, being held April 7-8 in Boston.

Dr. Waltzman’s panel, titled “Ensuring Effective and Efficient Trials Through Clinical Operations” will be Monday, April 7th from 4:05PM – 4:35PM ET.

Jeffrey Meckler, Indaptus CEO, commented, “These opportunities serve as continued validation for our approach to clinical trial management, reinforcing its potential to enhance efficiency, an essential factor in our industry. We appreciate this esteemed conference’s recognition and look forward to Roger’s panel, anticipating valuable insights from the discussion.”

The CMO Summit 360° ®, operated by The Conference Forum, is the largest gathering of biotech Chief Medical Officers across indications, modalities, company stages, professional experience levels and geographic locations. This is the conference to connect with peers and develop the skills needed to succeed as a biotech CMO. The Conference Forum is a life science industry research, conference development and marketing firm. The company brings the full spectrum of executives together to share ideas and information on how to advance efficient medicine development and delivery, patient diversity and access. 

About Indaptus Therapeutics

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas, pancreatic and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In pre-clinical studies tumor eradication was observed with Decoy product candidates in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product candidate, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product candidate. Indaptus’ Decoy product candidates have also produced meaningful single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

For more information, visit www.indaptusrx.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things, our expectations and plans regarding our Phase 1 clinical trial of Decoy20 and the anticipated effects of our product candidates, including Decoy20. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to the following: our limited operating history; conditions and events that raise substantial doubt regarding our ability to continue as going concern; the need for, and our ability to raise, additional capital given our lack of current cash flow; our clinical and preclinical development, which involves a lengthy and expensive process with an uncertain outcome; our incurrence of significant research and development expenses and other operating expenses, which may make it difficult for us to attain profitability; our pursuit of a limited number of research programs, product candidates and specific indications and failure to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success; our ability to obtain and maintain regulatory approval of any product candidate; the market acceptance of our product candidates; our reliance on third parties to conduct our preclinical studies and clinical trials and perform other tasks; our reliance on third parties for the manufacture of our product candidates during clinical development; our ability to successfully commercialize Decoy20 or any future product candidates; our ability to obtain or maintain coverage and adequate reimbursement for our products; the impact of legislation and healthcare reform measures on our ability to obtain marketing approval for and commercialize Decoy20 and any future product candidates; product candidates of our competitors that may be approved faster, marketed more effectively, and better tolerated than our product candidates; our ability to adequately protect our proprietary or licensed technology in the marketplace; the impact of, and costs of complying with healthcare laws and regulations, and our failure to comply with such laws and regulations; information technology system failures, cyberattacks or deficiencies in our cybersecurity; and unfavorable global economic conditions. These and other important factors discussed under the caption “Risk Factors” included in our most recent Annual Report on Form 10-K filed with the SEC on March 13, 2025, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.

Contact: investors@indaptusrx.com

Investor Relations Contact:
CORE IR
Louie Toma
louie@coreir.com


FAQ

When and where will Indaptus Therapeutics (INDP) participate in the CMO360 Summit 2025?

Indaptus Therapeutics will participate on April 7th, 2025, from 4:05PM to 4:35PM ET in Boston.

What panel will INDP's Chief Medical Officer moderate at the CMO360 Summit?

Dr. Roger Waltzman will moderate the panel 'Ensuring Effective and Efficient Trials Through Clinical Operations.'

What is the significance of INDP's participation in the CMO360 Summit?

The participation validates Indaptus's approach to clinical trial management and efficiency according to CEO Jeffrey Meckler.

What is the CMO360 Summit where INDP will be presenting?

It's the largest gathering of biotech Chief Medical Officers, covering various indications, modalities, company stages, and locations, operated by The Conference Forum.
Indaptus Therapeutics Inc

NASDAQ:INDP

INDP Rankings

INDP Latest News

INDP Stock Data

6.81M
7.72M
42.01%
14.2%
0.48%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK